{"filing":{"accession_number":"0001746473-26-000092","cik":"0001746473","ticker":"PLRX","company_name":"PLIANT THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"plrx-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/plrx-20260611.htm"},"events":[{"id":5533,"run_id":4853,"accession_number":"0001746473-26-000092","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 11, 2026. The filing reports final voting outcomes on three proposals: election of Class III directors (Proposal No. 1), advisory vote on named executive officer compensation (Proposal No. 2), and ratification of Deloitte \u0026 Touche LLP as independent auditor (Proposal No. 3), with detailed vote tallies certified by the Inspector of Elections. Shareholder voting outcomes are material to investors as they determine board composition and affirm governance decisions.","company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6411,"accession_number":"0001746473-26-000092","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 11, 2026. The filing reports final voting outcomes on three proposals: election of Class III directors (Proposal No. 1), advisory vote on named executive officer compensation (Proposal No. 2), and ratification of Deloitte \u0026 Touche LLP as independent auditor (Proposal No. 3), with detailed vote tallies certified by the Inspector of Elections. Shareholder voting outcomes are material to investors as they determine board composition and affirm governance decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:53:06.041224+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6411,"accession_number":"0001746473-26-000092","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 11, 2026. The filing reports final voting outcomes on three proposals: election of Class III directors (Proposal No. 1), advisory vote on named executive officer compensation (Proposal No. 2), and ratification of Deloitte \u0026 Touche LLP as independent auditor (Proposal No. 3), with detailed vote tallies certified by the Inspector of Elections. Shareholder voting outcomes are material to investors as they determine board composition and affirm governance decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:53:06.041224+00:00","company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","filing_date":"2026-06-11"}]}